This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Drug/Biotech Stock Q1 Earnings on May 9: IONS, XLRN & More
by Zacks Equity Research
Five drug/biotech stocks are scheduled to release their first-quarter results on May 9. Let's take a look at how these companies are poised ahead of their earnings release.
Array BioPharma (ARRY) Q3 Earnings and Sales Beat Estimates
by Zacks Equity Research
Array BioPharma's (ARRY) top and bottom lines beat estimates in the third quarter of fiscal 2019. Momentum in uptake of Braftovi-Mektovi combination therapy continues.
What's in the Cards for Nektar (NKTR) This Earnings Season?
by Zacks Equity Research
The focus will be on Nektar Therapeutics' (NKTR) pipeline progress when the company reports first-quarter results.
Conatus' (CNAT) Earnings, Revenues Miss Estimates in Q1
by Zacks Equity Research
Conatus, (CNAT) earnings and revenues lag estimates in the first-quarter of 2019. Emricasan remains in focus.
The Zacks Analyst Blog Highlights: Merck, Pfizer, AbbVie, Sanofi and Glaxo
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Merck, Pfizer, AbbVie, Sanofi and Glaxo
The Zacks Analyst Blog Highlights: Pfizer, Intel, HCA Healthcare, Xilinx and Cummins
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Intel, HCA Healthcare, Xilinx and Cummins
Pharma Stock Roundup: MRK, LLY, PFE Report Q1 Earnings, SNY, ABBV Drugs Get EU Nod
by Kinjel Shah
Merck (MRK), Pfizer (PFE), Lilly (LLY) announce Q1 results. European Commission grants approval to AbbVie's (ABBV) Skyrizi and Sanofi's (SNY) Zynquista.
Dow 30 Stock Roundup: AAPL, PFE, MRK, MCD Earnings Impress
by Swarup Gupta
The index traversed a mixed week, buoyed by encouraging earnings numbers and dragged lower by comments from the Fed Chair.
Top Stock Reports for Pfizer, Intel & HCA Healthcare
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Pfizer (PFE), Intel (INTC) and HCA Healthcare (HCA).
Exelixis (EXEL) Earnings & Revenues Beat Estimates in Q1
by Zacks Equity Research
Exelixis's (EXEL) earnings and revenues beat expectations in the first quarter on strong sales of Cabometyx.
Glaxo (GSK) Beats on Q1 Earnings & Sales, Shingrix Impresses
by Zacks Equity Research
Glaxo (GSK) beats earnings and sales estimates for the first quarter. Strong sales growth of vaccine portfolio boosts sales. However, Advair generic severely impacts the drug's U.S. sales.
Amgen (AMGN) Q1 Earnings Top, Sales Hurt by Pricing Pressure
by Zacks Equity Research
Amgen (AMGN) earnings beat estimates in the first quarter while sales come in line with the same. The company raises the lower end of its previously issued sales and earnings guidance for 2019.
Q1 Earnings Continue
by Zacks Equity Research
Q1 Earnings Continue
Big Day for Q1 Earnings: MCD, PFE, GE & More
by Mark Vickery
After today's close, we will hear from Apple Inc. (AAPL). This morning, here are a few of the big names reporting.
Pfizer (PFE) Beats on Q1 Earnings & Sales, Raises EPS View
by Zacks Equity Research
Pfizer (PFE) beat estimates for first-quarter earnings and sales and raised the mid-point of its earnings expectations for 2019 by a penny and confirmed its previous outlook for full-year sales.
Teladoc (TDOC) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Teladoc's (TDOC) Q1 earnings should benefit from increase in revenues, partly offset by rise in expenses.
Is a Beat in Store for Cigna (CI) This Earnings Season?
by Zacks Equity Research
Cigna's (CI) Q1 earnings should benefit from increase in revenues and membership.
Why Earnings Season Could Be Great for Pfizer (PFE)
by Zacks Equity Research
Pfizer (PFE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Sangamo (SGMO) Q1 Earnings: What's in Store for the Stock?
by Zacks Equity Research
For Sangamo's (SGMO) Q1, investor focus will be on its gene therapy candidate, SB-525, currently under evaluation for hemophilia A. The company also boasts several other early-stage promising candidates in its pipeline.
Bristol-Myers Q1 Earnings Beat, Sales Up on Strong Eliquis
by Zacks Equity Research
Bristol-Myers (BMY) Q1 earnings and sales beat estimates on strong performance of Eliquis and Opdivo.
What's in Store for SS&C Technologies (SSNC) in Q1 Earnings?
by Zacks Equity Research
SS&C Technologies (SSNC) efforts to strengthen its cloud-based and AI technologies are likely to drive the top line.
Pfizer (PFE) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $39.46, marking a +0.09% move from the previous day.
Lannett (LCI) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Lannet (LCI) will release fiscal third-quarter earnings and is expected to provide an update on product launches
Pfizer (PFE) to Report Q1 Earnings: Will It Beat Estimates?
by Kinjel Shah
While Pfizer's (PFE) key drugs like Ibrance and Xeljanz are likely to drive Q1 sales, genericization of key drugs and weak sales in the EH segment will hurt.
Amgen (AMGN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
While Amgen's (AMGN) growth drugs like Prolia & Xgeva may do well, biosimilar competition and slowdown in sales of mature products are likely to put pressure on sales growth.